Composition for promoting the growth of bifidobacteria

Abstract

The present invention belongs to the technical fields of microorganisms and culture media, and specifically relates to a composition for promoting the growth of bifidobacteria, which comprises β-glucan, N-acetylneuraminic acid, and lactoferrin, and has a mass ratio of the β-glucan, N-acetylneuraminic acid, and lactoferrin of (0.10-0.60):(0.08-0.70):(0.018-0.20) in terms of dry weight. This composition may be a culture medium having an excellent effect of promoting the growth of bifidobacteria under anaerobic conditions, or a food composition that can promote the growth of bifidobacteria in the human intestine after ingestion and further improve intestinal health.

Description

[Technical field]

[0001] The present invention belongs to the technical field of microorganisms and culture media, and specifically relates to a composition for promoting the growth of bifidobacteria. [Background technology]

[0002] β-glucan is widely present in the cell walls of microorganisms (e.g., yeast, bacteria, and fungi) and cereals (e.g., barley, wheat, and oats), and is the main material that constitutes biological cell walls, with various structures and functions. Microbial-derived β-glucan often contains β-1,6-glycosidic bonds in the branched chain, but glucose is often linked via β-1,3-glycosidic bonds to form the main component. On the other hand, plant-derived β-glucan has β-1,4-glycosidic bonds in addition to β-1,3-glycosidic bonds and β-1,6-glycosidic bonds. The health-promoting effects of β-glucan, such as antioxidant, antidiabetic, anti-inflammatory, and anti-obesity functions, have been widely studied. It has been reported that β-glucan cannot be hydrolyzed under the environmental conditions of saliva, stomach, and small intestine, and shows low bioavailability in the upper digestive tract like other dietary fibers, and passes through the digestive system without being decomposed, safely reaching the intestinal tract. β-glucan can regulate the structure and composition of intestinal flora by suppressing the growth of harmful intestinal bacteria and promoting the growth of healthy intestinal bacteria. Cited Document 1 discloses a complex prebiotic containing inulin, galactooligosaccharides, xylitol, β-glucan and mannooligosaccharides for increasing the number of intestinal Lactobacillus bacteria and intestinal Bifidobacterium bacteria.

[0003] N-acetylneuraminic acid (NANA), commonly known as sialic acid, is an endogenous nutrient monosaccharide. N-acetylneuraminic acid plays a central role in brain development, especially in the post-translational modification of neural cell adhesion molecules (NCAM). N-acetylneuraminic acid has been suggested to have potential and selective prebiotic activity for bifidobacteria, and recent studies have demonstrated that Bifidobacterium pseudocatenulatum Bif4, a commensal bacterium of the infant gut, contains 41 genes responsible for central carbohydrate metabolism and has a gene cluster for the uptake and metabolism of free N-acetylneuraminic acid, a mechanism by which the strain can utilize free N-acetylneuraminic acid released by other gut symbionts and positively impact gut health. Reference 2 discloses that the proliferation of bifidobacteria can be regulated by using a combination of oligosaccharides (2'-fucosyllactose, 3'-sialyllactose and 6'-sialyllactose) contained in breast milk. Reference 3 discloses that the abundance ratio of beneficial intestinal bacteria, such as bifidobacteria, lactobacillus and bacteroids flavus, can be increased and the abundance ratio of intestinal pathogens can be reduced by using a prebiotic composition of sialic acid oligosaccharides and fusion oligosaccharides.

[0004] Lactoferrin is considered to be a safe and effective ingredient that can promote iron absorption in humans, regulate cell growth, scavenge free radicals, and inhibit the production of some toxic compounds. In addition, lactoferrin has antibacterial, anti-inflammatory, and anticancer activities, highlighting the therapeutic value of this multifunctional protein. Reference 4 discloses the use of lactoferrin in promoting the growth of bifidobacteria and Lactobacillus. Reference 5 discloses that a composition of lactoferrin and / or lactoferrin hydrolysate and human milk oligosaccharides can exert a synergistic growth-promoting effect on bifidobacteria.

[0005] Bifidobacterium pseudocatenulatum is the predominant bifidobacterium in the intestines of healthy adults, and is ubiquitously present in people of all age groups, with abundant bacterial resources. Several strains of this species have been proven to have probiotic functions, such as improving glycolipid metabolism, regulating immune function, and improving anxiety and depression. However, since Bifidobacterium pseudocatenulatum is not included in the list of bacteria species that can be used in foods under legal regulations, it is not possible to directly supplement Bifidobacterium pseudocatenulatum exogenously to increase its abundance in the human intestine, and it is only possible to indirectly stimulate the growth of Bifidobacterium pseudocatenulatum by exogenously supplementing certain substances. Reference 6 discloses the anabolic effect of bifidobacteria on human milk oligosaccharides. Reference 7 discloses that Bifidobacterium pseudocatenulatum can efficiently utilize galactooligosaccharides. Until now, most of the conventional techniques that have investigated substances that promote the growth of Bifidobacterium pseudocatenulatum have been related to galactooligosaccharides and human milk oligosaccharides, and there have been no techniques that describe the action and effect of a β-glucan, N-acetylneuraminic acid, and lactoferrin composition for promoting the growth of Bifidobacterium pseudocatenulatum. In addition, the dosage effect of a composition that promotes the growth of a specific bifidobacterium has not been reported in the conventional techniques. [Prior art documents] [Patent documents]

[0006] Cited document 1: CN108777998B Cited document 2:EP14177597 Cited document 3: EP13775460 Cited document 4: CN112375727B Cited document 5: CN113950247A Cited document 6: CN111935995A Cited document 7: CN113122471B Summary of the Invention [Problem to be solved by the invention]

[0007] In the above-mentioned conventional techniques, the research on the substance that promotes the growth of Bifidobacterium pseudocatenulatum is not sufficient. Furthermore, the present invention aims to develop a composition that promotes the growth of Bifidobacterium pseudocatenulatum in the intestine by examining the utilization ability of Bifidobacterium pseudocatenulatum in β-glucan, N-acetylneuraminic acid, lactoferrin and their compositions, and examining the dosage effect of the three substances and compositions. [Means for solving the problem]

[0008] In order to solve the above-mentioned problems of the conventional technology, the present invention provides the following aspects.

[0009] [1] First, the present invention provides a medium composition comprising basic nutritional components and supplemental components including β-glucan, N-acetylneuraminic acid, and lactoferrin, The medium composition has a mass ratio of β-glucan, N-acetylneuraminic acid and lactoferrin of (0.10-0.60):(0.08-0.70):(0.018-0.20) in terms of dry weight. [2] The composition described in [1], wherein the β-glucan is yeast β-glucan, and the N-acetylneuraminic acid is milk-derived N-acetylneuraminic acid, bird's nest-derived N-acetylneuraminic acid, or N-acetylneuraminic acid obtained by biofermentation. [3] The composition described in [1] or [2], wherein the basic nutritional components include one or more of a protein component, a lipid component, a sugar component, a vitamin component, a mineral component, and a pH adjusting component. [4] Use of the composition described in any one of [1] to [3] in promoting the growth of bifidobacteria, wherein the composition is used to promote the growth of bifidobacteria under anaerobic conditions. [5] The present invention further provides a composition having a proliferation-promoting effect on intestinal bifidobacteria, which contains β-glucan, N-acetylneuraminic acid and lactoferrin and has a mass ratio of the β-glucan, N-acetylneuraminic acid and lactoferrin of (0.10-0.60):(0.08-0.70):(0.018-0.20), in terms of dry weight. [6]. A composition having the effect of promoting the proliferation of intestinal bifidobacteria described in [5], wherein the bifidobacteria include one or more of Bifidobacterium pseudocatenulatum, Bifidobacterium adolescentis, Bifidobacterium infantis, Bifidobacterium bifidum, Bifidobacterium longum, and Bifidobacterium breve. [7] A composition having the effect of promoting the proliferation of intestinal bifidobacteria described in [5] or [6], optionally containing other nutritional ingredients. [8] A composition having the effect of promoting the proliferation of intestinal bifidobacteria described in any one of [5] to [7], which is liquid, semi-solid or solid. [9] The present invention further provides a food product comprising a composition having an effect of promoting the proliferation of intestinal bifidobacteria described in any one of [5] to [8], or prepared from the composition.

[10] . The food according to [9], which is a powdered drink, a bakery food, a beverage, a candy, milk and dairy products, a fermented product, a flour product or an oral preparation, preferably wherein the oral preparation includes tablets, pills, granules, powders, teas, capsules and oral liquid preparations. Effect of the Invention

[0010] By implementing the above aspects of the present invention, the following effects can be obtained. First, unlike conventional techniques which only examined the proliferation effects of several substances alone (e.g., human milk oligosaccharides, galactooligosaccharides) on Bifidobacterium pseudocatenulatum, the present invention examined the proliferation effect of a composition of β-glucan, N-acetylneuraminic acid and lactoferrin on bifidobacteria, particularly Bifidobacterium pseudocatenulatum, and surprisingly found that the proliferation-promoting effect of the composition on bifidobacteria was more pronounced than that of β-glucan, N-acetylneuraminic acid or lactoferrin alone, and that there was a synergistic effect between β-glucan, N-acetylneuraminic acid and lactoferrin.

[0011] In addition, the present invention comprehensively considers the necessary content of each component in the composition, and designs the dosage of each component in the composition when the proliferation of bifidobacteria, especially Bifidobacterium pseudocatenulatum, is relatively good under the condition of a single substance, and then increases and decreases the dosage to finally determine the appropriate dosage range. The composition of the present invention can provide many nutrients to bifidobacteria under the appropriate dosage conditions of each component, extend the stationary phase of bifidobacteria, delay the decline phase, and effectively promote the proliferation of bifidobacteria.

[0012] Additionally, the above-mentioned composition also promotes the proliferation of Bifidobacterium pseudocatenulatum, a potential probiotic, in the intestinal tract, improving intestinal health. [Brief description of the drawings]

[0013] [Figure 1] This figure shows the results of observing the growth of Bifidobacterium pseudocatenulatum after culturing it for 36 hours in MRS medium with different amounts of glucose added. From the left, the glucose concentrations of the medium in the test tubes are 2g / 100mL, 1g / 100mL, 0.5g / 100mL, 0.25g / 100mL, and 0.15g / 100mL. [Diagram 2]Growth curves of Bifidobacterium pseudocatenulatum in MRS medium supplemented with different doses of β-glucan. [Diagram 3] Growth curves of Bifidobacterium pseudocatenulatum in MRS medium supplemented with different doses of N-acetylneuraminic acid. [Figure 4] Growth curves of Bifidobacterium pseudocatenulatum in MRS medium supplemented with different doses of lactoferrin. [Diagram 5] Growth curves of Bifidobacterium pseudocatenulatum in MRS medium supplemented with different doses of β-glucan, N-acetylneuraminic acid and lactoferrin compositions. [Figure 6] OD values ​​of stationary phase cultures of Bifidobacterium pseudocatenulatum in MRS medium supplemented with different doses of β-glucan, N-acetylneuraminic acid and lactoferrin composition, where lowercase letters indicate the significance of the difference in OD values ​​between groups (p<0.05). If the OD values ​​of both groups do not contain the same letters, it indicates that there is a significant difference between the two, otherwise it indicates that there is no significant difference. [Figure 7] This is a statistical result of the change over time in ΔOD600nm of Bifidobacterium pseudocatenulatum liquid in MRS medium supplemented with different doses of β-glucan, N-acetylneuraminic acid, and lactoferrin composition. DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS

[0014] The following describes the embodiments of the present invention, but the present invention is not limited thereto. The present invention is not limited to the configurations described below, and various modifications are possible within the scope of the claims. The embodiments and examples obtained by appropriately combining the technical means disclosed in the different embodiments and examples are also included in the technical scope of the present invention.

[0015] definition In this specification, a numerical range expressed as "numeric value A to numerical value B" means a range including the limit values ​​A and B. In this specification, a numerical range expressed as "greater than or equal to" or "less than or equal to" means a numerical range that includes the indicated number. In this specification, the term "may" means that the treatment may or may not be carried out. As used herein, "optional" or "optional" refers to the use or non-use of an element such as a substance, ingredient, step, application condition, etc. Unless otherwise specified in this specification, the term "room temperature" generally means a temperature of 23±2°C. In this specification, all unit names used are international standard unit names, and unless otherwise specified, "%" used means percentage by weight or mass. In this specification, the terms "about", "basic" or "substantially" are used to indicate that a value includes the standard deviation of the error of the device or method used to determine the value. All numerical ranges and parameters used to define the present invention are approximate, but reproduce the numerical values ​​according to the specific examples as accurately as possible. However, any numerical value inherently includes the standard deviation of the above-mentioned measuring device or method. Therefore, unless otherwise specified, the ranges, numbers, values ​​and percentages used in the present invention should be understood to be modified by "about" in all cases. Here, "about" usually means that the standard deviation between the actual numerical value and the theoretical model or theoretical data is within 3%, preferably 2%, more preferably 1%. As used herein, references to "some / preferred embodiments," "another / preferred embodiment," "an embodiment," etc., mean that a particular element (e.g., a feature, structure, property, and / or characteristic) described in connection with an embodiment is included in at least one embodiment and may or may not be present in other embodiments. Also, such elements may be combined in any suitable manner in the various embodiments. Moreover, unless otherwise defined, other technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this invention belongs.

[0016] The present invention has been made mainly based on the following findings. First, in some typical embodiments of the present invention, bifidobacteria were cultured in MRS medium with glucose addition amounts of 2 g / 100 mL, 1 g / 100 mL, 0.5 g / 100 mL, 0.25 g / 100 mL, and 0.15 g / 100 mL, respectively, and it was found that the growth rate of bifidobacteria was appropriate in MRS medium with a glucose addition amount of 0.15 g / 100 mL, making it suitable for subsequent experiments.

[0017] Furthermore, in the present invention, it was found that β-glucan alone can promote the growth of bifidobacteria, and the amount of β-glucan added to the culture medium can be 0.2550 to 0.5738 mg / mL; N-acetylneuraminic acid alone can promote the growth of bifidobacteria, and the amount of N-acetylneuraminic acid added to the culture medium can be 0.2058 to 0.5145 mg / mL; and lactoferrin alone can promote the growth of bifidobacteria, and the amount of lactoferrin added to the culture medium can be, for example, 0.0459 mg / mL.

[0018] Furthermore, the present invention adopts a method of combining multiple substances, and since different substances have different properties and different substances have different mechanisms of decomposition of probiotics, a combination of multiple substances can promote the growth of beneficial bacteria more effectively than a single substance. The present invention has been measured through a large number of experiments and found that adding β-glucan, N-acetylneuraminic acid and lactoferrin to a medium at a specific ratio (e.g., concentration) can promote the growth of bifidobacteria, especially Bifidobacterium pseudocatenulatum, more effectively. Based on this, the present invention provides a composition that can effectively promote the growth of bifidobacteria, and shows a better effect than adding each of the three substances alone, with the growth rate at the stationary phase being 1.8 times that of the blank control group, which is the most effective effect.

[0019] The embodiments of the present invention will be further described below.

[0020] Medium composition First, the present invention provides a medium composition comprising basic nutritional components and supplementary components including β-glucan, N-acetylneuraminic acid and lactoferrin. The composition has been shown to have a significant synergistic effect and can effectively promote the growth of bifidobacteria, especially the growth of Bifidobacterium pseudocatenulatum, under anaerobic conditions.

[0021] (Basic nutritional components) There are no particular limitations on the basic nutritional components that can be used in the medium composition of the present invention, and any components that are generally used in conventional MRS media may be used. In some embodiments, such basic nutritional components include one or more of a protein component, a lipid component, a sugar component, a vitamin component, a mineral component, and a pH adjusting component.

[0022] In the present invention, there is no particular requirement regarding the proportions of these components used, and they may be set in accordance with the usual technical guidelines in the prior art. In some preferred embodiments of the present invention, the medium may contain ingredients such as tryptone, yeast powder, beef extract, glucose, magnesium sulfate heptahydrate, manganese sulfate monohydrate, sodium acetate, diammonium hydrogen citrate, dipotassium hydrogen phosphate trihydrate, and polysorbate 80.

[0023] (β-glucan) Beta-glucan is a type of polysaccharide derived from cell walls. Current research has shown that beta-glucan has health-promoting effects such as immunomodulatory, antitumor, and blood lipid lowering effects, and can effectively promote the establishment of probiotic flora such as bifidobacteria in the intestine, effectively alleviating various gastrointestinal digestive problems. At present, the extraction process of β-glucan is relatively mature, so in the present invention, the extraction process of said β-glucan is not particularly limited, for example, it can be extracted by acid hydrolysis using acetic acid, alkali extraction using sodium hydroxide, or a combination of acid and alkali. In addition, the finished β-glucan product can be obtained commercially.

[0024] Furthermore, in the present invention, the origin of the β-glucan is not particularly limited, and it may be β-glucan derived from various plants, fungi, algae, etc., such as oats, barley, yeast, mushrooms, seaweed, etc. In some preferred embodiments of the present invention, from the viewpoint of better promoting the growth of bifidobacteria, the β-glucan may be β-glucan derived from yeast, which is a polymeric polysaccharide having β-1,3-D-glucan as the main chain and β-1,6-D-glucan as the branched chain.

[0025] (N-acetylneuraminic acid) N-acetylneuraminic acid, also known as sialic acid (NANA), is an important component of brain gangliosides. Research has shown that N-acetylneuraminic acid is widely present in various biological tissues and is an important component of glycoproteins, oligosaccharides and glycolipids. It is usually present as a glycoside at the terminal of glycoproteins and glycolipids, and is particularly abundant in mammalian brains, nervous tissues, blood, submandibular gland, mucin, colostrum, etc. N-acetylneuraminic acid has beneficial effects in various aspects, such as promoting intellectual development, improving intestinal absorption capacity, and improving immunity. Research has also shown that N-acetylneuraminic acid may have potential and selective prebiotic activity against bifidobacteria. Currently, methods for producing N-acetylneuraminic acid mainly include natural material extraction, chemical synthesis, polymer decomposition, enzyme / immobilized enzyme method, microbial fermentation, etc. In the present invention, the origin and extraction process of N-acetylneuraminic acid are not particularly limited, and for example, N-acetylneuraminic acid derived from milk, N-acetylneuraminic acid derived from bird's nest, N-acetylneuraminic acid obtained by biofermentation, or commercially available finished N-acetylneuraminic acid may be used.

[0026] (Lactoferrin) Lactoferrin (LF) is an iron-binding glycoprotein with a molecular weight of 80 kDa and belongs to the transferrin family. Lactoferrin is widely distributed in human and mammalian milk, as well as in various tissues and their secretions. It is highly abundant in milk, with bovine colostrum having the highest lactoferrin content. Research has shown that lactoferrin has a wide range of functions, including a broad antibacterial spectrum, antiviral infection, regulating the balance of iron in the body, regulating the production of bone marrow cells, promoting cell proliferation, regulating the immune function of the body, enhancing the immune power of the body, and suppressing human tumor cells. Research has also shown that lactoferrin can promote the proliferation of bifidobacteria and lactic acid bacteria, and maintain a healthy microbial environment in the intestines. In the present invention, there are no particular limitations on the origin or production method of lactoferrin. For example, lactoferrin can be isolated from milk using separation and purification methods such as chromatography and ultrafiltration, exogenously expressed lactoferrin can be obtained using recombinant protein expression technology, or finished lactoferrin can be obtained commercially.

[0027] (Synergy) Previous studies on β-glucan, N-acetylneuraminic acid and lactoferrin have shown that all three may have the effect of promoting the growth of Bifidobacterium bacteria. However, conventional techniques have only studied the three substances individually, and there has been no research or report on whether there is a synergistic effect between the three to promote the growth of Bifidobacteria.

[0028] In the present invention, it was unexpectedly discovered that the combined use of β-glucan, N-acetylneuraminic acid and lactoferrin exhibits a synergistic effect in promoting the growth of bifidobacteria, particularly Bifidobacterium pseudocatenulatum, under anaerobic conditions. The dosage required for the combined use is different from the dosage required for each of the three substances used alone to promote the growth of Bifidobacterium pseudocatenulatum.

[0029] The present invention first designed and investigated the proliferation of Bifidobacterium pseudocatenulatum using a single substance, and found the proliferation effect of different doses of a single substance on Bifidobacterium pseudocatenulatum.

[0030] In some embodiments, β-glucan alone has the effect of promoting the growth of Bifidobacterium pseudocatenulatum when the concentration is 0.2550 to 0.5738 mg / mL.

[0031] In some embodiments, N-acetylneuraminic acid alone has the effect of promoting the growth of Bifidobacterium pseudocatenulatum when the concentration is 0.2058 to 0.5145 mg / mL.

[0032] In some embodiments, lactoferrin alone at a concentration of 0.0459 mg / mL is effective in promoting the growth of Bifidobacterium pseudocatenulatum.

[0033] Further investigation into the present invention has revealed that the dosage required when β-glucan, N-acetylneuraminic acid and lactoferrin are used in combination is different from the dosage required when each of the above substances is used alone to promote the growth of Bifidobacterium pseudocatenulatum.

[0034] Specifically, the following applies:

[0035] In the above medium composition, the mass ratio of β-glucan, N-acetylneuraminic acid and lactoferrin according to the present invention is (0.10-0.60):(0.08-0.70):(0.018-0.20) in terms of dry weight.

[0036] In some preferred embodiments, the mass ratio of the β-glucan, N-acetylneuraminic acid, and lactoferrin may be (0.11-0.59):(0.09-0.68):(0.020-0.15), and more preferably may be (0.12-0.55):(0.10-0.60):(0.021-0.11). For example, the mass ratio of the β-glucan, N-acetylneuraminic acid, and lactoferrin may be 0.255:0.50:0.05, or 0.255:0.21:0.05, or 0.51:0.40:0.09, or 0.51:0.10:0.05, or 0.13:0.57:0.023, etc.

[0037] Furthermore, in the present invention, the amounts of β-glucan, N-acetylneuraminic acid and lactoferrin used are not limited in principle, so long as the above mass ratios are satisfied and the synergistic effect and safety of the amounts used can be ensured.

[0038] In the present invention, the form of the medium composition is not particularly limited, but in some embodiments, the medium composition according to the present invention may contain a solvent, such as water, etc. Therefore, the form may be, for example, a liquid (such as an aqueous solution) or a semi-solid (such as a slurry).

[0039] Use of a medium having the above composition has an excellent growth promoting effect on bifidobacteria, particularly Bifidobacterium pseudocatenulatum, under anaerobic conditions.

[0040] Composition having the effect of promoting the proliferation of intestinal bifidobacteria Furthermore, the present invention provides a composition having an effect of promoting the proliferation of intestinal bifidobacteria, which contains the above-mentioned β-glucan, N-acetylneuraminic acid and lactoferrin, and optionally other nutritional components.

[0041] The relationship between the amounts of β-glucan, N-acetylneuraminic acid, and lactoferrin used can be a mass ratio relationship of (0.10-0.60):(0.08-0.70):(0.018-0.20). In some preferred embodiments, the mass ratio of the β-glucan, N-acetylneuraminic acid, and lactoferrin may be (0.11-0.59):(0.09-0.68):(0.020-0.15), and more preferably (0.12-0.55):(0.10-0.60):(0.021-0.11). Similarly, as long as the above ratios are satisfied, there are no particular restrictions on the mass contents of β-glucan, N-acetylneuraminic acid and lactoferrin in the composition, but they may be added in amounts normally used and in accordance with the requirements of relevant laws and regulations.

[0042] In some embodiments, the bifidobacterium of the present invention includes one or more of Bifidobacterium pseudocatenulatum, Bifidobacterium adolescentis, Bifidobacterium infantis, Bifidobacterium bifidum, Bifidobacterium longum, and Bifidobacterium breve. The bifidobacterium bacteria can colonize the human intestine.

[0043] In particular, the composition of the present invention can promote the proliferation of Bifidobacterium pseudocatenulatum in the intestine. Although Bifidobacterium pseudocatenulatum is a beneficial intestinal bacterium, it does not belong to the species of bacteria that can be used in foods as permitted by law. Therefore, the composition of the present invention having the effect of promoting the proliferation of intestinal bifidobacteria has special significance in that it can promote human health by utilizing the beneficial effects of Bifidobacterium pseudocatenulatum by exerting the proliferation-promoting effect of Bifidobacterium pseudocatenulatum in the intestine.

[0044] In addition to the β-glucan, N-acetylneuraminic acid and lactoferrin required for the composition, the composition of the present invention having the effect of promoting the proliferation of intestinal bifidobacteria may optionally contain other nutritional components depending on the edible requirements of the final product, such as plants or extracts thereof, milk-containing components, animal components, functional additive components, trace element supplements and / or any food-acceptable additives.

[0045] Examples of plants or plant extracts include fruits such as figs, pomegranates, kiwi fruit, mandarins, bitter oranges, pineapples, strawberries, apples, rubber trees, grapes, pears, cherries, blueberries, blackberries, raspberries, and bilberries, or extracts thereof; vegetables such as onions, cucumbers, tomatoes, cauliflower, carrots, spinach, Chinese broccoli, Brussels sprouts, garlic, basil, and oregano, or extracts thereof; rice (Indica rice, Dioscorea sativa, and others), and other vegetables such as cucumbers, tomatoes, cauliflower, carrots, spinach, Chinese broccoli, Brussels sprouts, garlic, basil, and oregano. Cereals or extracts thereof, such as japonica rice, glutinous rice, wheat (wheat, barley, oats, rye), corn, sorghum, foxtail millet, millet, buckwheat, soybeans, broad beans, peas, mung beans, adzuki beans, kidney beans, etc.; nut substances or extracts thereof, such as walnuts, pistachios, cashew nuts, hazelnuts, almonds, apricot kernels, pine nuts, peanuts, guava, chestnuts, macadamia nuts, ginkgo nuts, etc.; coffee or its extracts.

[0046] Regarding the milk-containing or protein components, the milk-containing components include dairy products such as raw milk derived from cow's (goat's) raw milk, milk powder, whey protein or cheese, etc. Regarding the protein components, they may be derived from plant proteins such as soy protein, peanut protein, etc.

[0047] Animal ingredients include meat product ingredients derived from bovine, caprine, fish or poultry.

[0048] Regarding the fat component, the fat includes at least one of saturated fatty acids, polyunsaturated fatty acids, monounsaturated fatty acids, 1,3-dioleoyl-2-palmitoylglycerol (OPO), DHA, EPA, ARA, and phospholipids, and specifically, the fat includes safflower oil, walnut oil, peanut oil, soybean oil, argan oil, olive oil, tea oil, sacha inchi oil, olive oil, coconut oil, perilla oil, deep-sea fish oil, cocoa cream, palm oil, beef tallow, cream, lard, medium-chain triglyceride, or lecithin.

[0049] The functional additive ingredients include vitamins (including one or more of vitamin A, β-carotene, vitamin D3, vitamin E, vitamin K1, vitamin B1, vitamin B2, vitamin B6, vitamin B12, vitamin C, pantothenic acid, folic acid, nicotinic acid, choline, inositol, and biotin), starch, modified starch, amino acids (L-lysine-L-glutamic acid, L-glutamic acid, L-arginine, L-tryptophan, L-glutamine, taurine, L-valine, L-isoleucine, L-leucine, etc.), herbal medicines or herbal medicine extracts, and dietary fiber (inulin, konjac flour, galactooligosaccharides, fructooligosaccharides, isomaltooligosaccharides, soybean polysaccharides, cyclodextrin, resistant dextrin, soybean fiber, etc.).

[0050] Trace element supplements include one or more of metal ion salts of organic acids, such as calcium citrate, calcium L-lactate, calcium hydrogen phosphate, potassium gluconate, sodium citrate, ferrous gluconate, potassium iodide, zinc gluconate, sodium selenite, copper gluconate, chromium sulfate, manganese gluconate, and magnesium gluconate.

[0051] Optional food acceptable additives include, but are not limited to, solvents, antioxidants, antimicrobial agents, thickeners, diluents, co-solvents, stabilizers, emulsifiers, fillers, disintegrants, lubricants, coating materials, anti-caking agents, flavoring agents, sweeteners, food flavorings, food colors, and the like.

[0052] Furthermore, the form of the composition having the effect of promoting the proliferation of intestinal bifidobacteria of the present invention is not particularly limited, and it may be, for example, liquid, semi-solid, or solid.

[0053] food The present invention provides a food product comprising the composition or a composition having an effect of promoting the proliferation of intestinal bifidobacteria. The food of the present invention is not particularly limited, but may generally be a powdered drink, bakery food, beverage, candy, milk and dairy products, fermented products, flour products or oral preparations.

[0054] The powdered drink may typically be a powdered milk product, such as infant milk powder, adult milk powder, or instant coffee, grain powder, nut powder, lotus root powder, or the like.

[0055] The bakery food may be a bakery cake or a biscuit, etc., whose main ingredients are cream, eggs and baking powder.

[0056] The beverages may include carbonated beverages, fruit juice or vegetable juice beverages, functional beverages, tea beverages, dairy beverages, alcoholic beverages, and the like.

[0057] Candies may include hard candies, hard candies containing centers, fudge, gummy candies, polishing candies, gum-based candies, aeration candies, tablet candies, and the like.

[0058] Milk and dairy products may include raw milk derived from cow's (goat's) raw milk, milk powder, whey powder, fermented milk, cheese, condensed milk, and the like.

[0059] The fermented product may typically be fermented milk, fermented soy milk, etc., and may include a fermented sauce.

[0060] Wheat flour products may include staple foods processed or manufactured using wheat flour as a raw material, as well as multigrain staple foods, and specific examples include steamed bread, rice cakes, noodles, and bean paste staple foods.

[0061] Oral formulations may include tablets, pills, granules, powders, teas, capsules and oral liquids.

[0062] The food products provided by the invention are in principle suitable for everyone, especially those who have a need to improve their intestinal health, and it is also possible to adjust the ingredients in the food products for people with different characteristics.

[0063] In some embodiments, the content of the β-glucan is 0.05 to 0.5%, preferably 0.06 to 0.4%, more preferably 0.06 to 0.35%, and even more preferably 0.1 to 0.25%, the content of the N-acetylneuraminic acid is 0.01 to 0.3%, preferably 0.015 to 0.2%, more preferably 0.02 to 0.15%, and even more preferably 0.025 to 0.1%, and the content of the lactoferrin is 0.01 to 0.1%, preferably 0.01 to 0.07%, more preferably 0.01 to 0.05%, and even more preferably 0.01 to 0.03%, based on the total mass of the food. Typically, the food may be powdered milk, particularly powdered milk for infants, powdered milk for children, powdered milk for the middle-aged and elderly, and the like. EXAMPLES

[0064] In order to make the objectives, technical solutions and advantages of the present invention clearer, the present invention will be described in more detail with reference to the following examples. It should be understood that the specific examples described herein are only for illustrating the present invention, and are not intended to limit the present invention. Unless otherwise specified, the reagents, methods and equipment used in the present invention are common reagents, methods and equipment in the art.

[0065] The method for producing Bifidobacterium pseudocatenulatum cells according to the following examples is as follows. Bifidobacterium pseudocatenulatum strain (original number: 8-7, hereafter referred to as "Bifidobacterium pseudocatenulatum") was derived from a fecal sample of a healthy infant from Wuxi City, Jiangsu Province, and was stored in the Biotechnology Center of the School of Food Science, Jiangnan University. Bifidobacterium pseudocatenulatum was activated by an activation process. First, Bifidobacterium pseudocatenulatum glycerol tubes were cultured in liquid MRS medium with a bacterial load of 2% (V / V) and cultured under anaerobic conditions at 37 °C for 36 h. Then, Bifidobacterium pseudocatenulatum was streaked on mMRS (mMRS is MRS supplemented with 0.05% cysteine) solid medium and cultured under anaerobic conditions at 37 °C for 36 h to obtain single colonies. A single colony was picked and inoculated into 5 mL of mMRS liquid medium, and activated by culturing for 36 hours under anaerobic conditions at 37°C, and two generations were successively activated to obtain an activated liquid. The bacteria were thawed and activated, and then used for subsequent tests.

[0066] Furthermore, all of the glucans used in the following examples are commercially available yeast β-glucans.

[0067] Example 1: Growth of Bifidobacterium pseudocatenulatum in MRS medium with different glucose contents The above-mentioned Bifidobacterium pseudocatenulatum was inoculated into mMRS liquid medium with different glucose addition amounts (2g / 100mL, 1g / 100mL, 0.5g / 100mL, 0.25g / 100mL, and 0.15g / 100mL, respectively), and after anaerobic culture at 37°C for 48 hours, the growth status of Bifidobacterium pseudocatenulatum was observed. As shown in Figure 1 (the glucose concentration of the medium in the test tube decreases from left to right), after 36 hours, Bifidobacterium pseudocatenulatum grew slowly in the MRS medium containing 0.15g / 100mL glucose, and barely maintained growth. Therefore, for subsequent experiments on the promotion of Bifidobacterium pseudocatenulatum growth by β-glucan, N-acetylneuraminic acid, and lactoferrin, the glucose concentration in the reduced-sugar MRS medium was set to 0.15 g / 100 mL.

[0068] Example 2: Growth of Bifidobacterium pseudocatenulatum in MRS medium with different doses of β-glucan The concentration of commercially available powdered milk preparation was used as the standard, and the liquid concentration of β-glucan, 0.06375 mg / mL, was set as the standard dosage.Based on the standard dosage, the dosages were set at 1 / 4, 1 / 2, 1, 2, 4, and 9 times (however, 9 times is the maximum amount allowed by law), resulting in β-glucan concentrations of 0.01594 mg / mL, 0.03188 mg / mL, 0.06375 mg / mL, 0.1275 mg / mL, 0.2550 mg / mL, and 0.5738 mg / mL, respectively. 1 mL of the bacterial solution of Bifidobacterium pseudocatenulatum that had been continuously activated for two generations was placed in a sterile centrifuge tube and centrifuged at 5000 r / min for 15 minutes. The upper layer medium was discarded to obtain bacterial sludge, which was then resuspended in 1 mL of sterile saline and inoculated into reduced-sugar MRS medium containing the six different doses of β-glucan mentioned above at an inoculum volume of 2% (V / V). As a blank control, reduced-sugar MRS medium without β-glucan was inoculated, placed in a microplate reader, and cultured anaerobically at 37°C for 36 hours. During the culture, the OD of the culture solution was measured. 600 The growth curves of B. pseudocatenulatum on different doses of β-glucan are shown in Figure 2.

[0069] As can be seen from Figure 2, B. pseudocatenulatum entered the logarithmic growth phase at almost the same time in the culture medium containing six different doses of β-glucan and the control culture medium. Compared with the control culture medium, B. pseudocatenulatum had higher absorbance values ​​and the highest total bacterial counts in the stationary phase in the culture medium containing 4 and 9 times the standard dose of β-glucan. In particular, when the β-glucan content was 4 times the standard dose, the OD 600 The results showed that the utilization of β-glucan by Bifidobacterium pseudocatenulatum was dose-dependent, and that β-glucan at concentrations 4-9 times the standard dose (0.2550-0.5738 mg / mL) promoted the growth of Bifidobacterium pseudocatenulatum.

[0070] Example 3: Growth of Bifidobacterium pseudocatenulatum in MRS medium with different doses of N-acetylneuraminic acid The concentration of commercially available powdered milk preparation was used as the standard, and the liquid concentration of N-acetylneuraminic acid, 0.05145 mg / mL, was set as the standard dosage. Based on the standard dosage, the dosages were set to 1 / 4, 1 / 2, 1, 2, 4, 10, and 22 times (however, 22 times is the maximum amount allowed by law), resulting in N-acetylneuraminic acid concentrations of 0.01286 mg / mL, 0.02573 mg / mL, 0.05145 mg / mL, 0.1029 mg / mL, 0.2058 mg / mL, 0.5145 mg / mL, and 1.1319 mg / mL, respectively. 1 mL of the bacterial solution of Bifidobacterium pseudocatenulatum that had been continuously activated for two generations was placed in a sterile centrifuge tube and centrifuged at 5000 r / min for 15 minutes. The upper layer medium was discarded to obtain bacterial slurry, which was then resuspended in 1 mL of sterile saline and inoculated into reduced-sugar MRS medium supplemented with the seven different doses of N-acetylneuraminic acid at an inoculum volume of 2% (V / V). As a blank control, reduced-sugar MRS medium without N-acetylneuraminic acid was inoculated, placed in a microplate reader, and cultured anaerobically at 37°C for 36 hours. During the culture, the OD of the culture was measured. 600The growth curves of B. pseudocatenulatum at different doses of N-acetylneuraminic acid are shown in Figure 3.

[0071] As is clear from Figure 3, B. pseudocatenulatum entered the logarithmic growth phase at almost the same time in the culture medium containing seven different doses of N-acetylneuraminic acid and the control culture medium. However, compared to the control, B. pseudocatenulatum had a larger absorbance value in the stationary phase, the highest total bacterial count, and the highest OD in the culture medium containing 4 to 10 times the standard dose of N-acetylneuraminic acid. 600 The results showed that the utilization of N-acetylneuraminic acid by Bifidobacterium pseudocatenulatum was dose-dependent, and that N-acetylneuraminic acid at concentrations 4-10 times the standard dose (0.2058-0.5145 mg / mL) promoted the growth of Bifidobacterium pseudocatenulatum.

[0072] Example 4: Growth of Bifidobacterium pseudocatenulatum in MRS medium with different doses of lactoferrin The concentration of commercially available powdered milk was used as the standard, and the liquid concentration of lactoferrin was 0.0459 mg / mL as the standard dosage. Based on the standard dosage, two gradients (2x and 4x) were set up above and two gradients (1 / 2 and 1 / 4) were set down below to obtain lactoferrin cultures with a total of five different concentrations. However, the 4x standard dosage exceeds the upper limit of the amount of addition permitted by law. Therefore, the lactoferrin concentrations were set to 0.01148 mg / mL, 0.02295 mg / mL, 0.0459 mg / mL, 0.0918 mg / mL, and 0.1500 mg / mL, respectively. 1 mL of the bacterial solution of Bifidobacterium pseudocatenulatum that had been continuously activated for two generations was placed in a sterile centrifuge tube and centrifuged at 5000 r / min for 15 minutes. The upper layer medium was discarded to obtain bacterial slurry, which was then resuspended in 1 mL of sterile saline and inoculated into reduced-sugar MRS medium containing the above five different doses of lactoferrin at an inoculum volume of 2% (V / V). As a blank control, the reduced-sugar MRS medium was inoculated without lactoferrin. The plate was placed in a microplate reader and cultured anaerobically at 37°C for 36 hours. During the culture, the OD of the culture was measured. 600 The growth curves of B. pseudocatenulatum at different doses of lactoferrin are shown in Figure 4.

[0073] As is clear from Figure 4, Bifidobacterium pseudocatenulatum entered the logarithmic growth phase at approximately the same time in the culture medium containing the five different doses of lactoferrin and in the control culture medium. However, compared to the control, Bifidobacterium pseudocatenulatum had higher absorbance values ​​and the highest total bacterial counts in both the logarithmic and stationary phases at the standard dose (1x) of lactoferrin. During the logarithmic growth phase, Bifidobacterium pseudocatenulatum had higher OD values ​​at 1 / 4 and 2x the standard dose of lactoferrin. 600 The OD of B. pseudocatenulatum was lower than that of the control group at the stationary phase, and the OD of B. pseudocatenulatum was higher at half and four times the standard dose of lactoferrin. 600The results showed that an appropriate dose of lactoferrin is necessary to promote the growth of Bifidobacterium pseudocatenulatum, and that if the dose is too high or too low, the growth promotion effect of Bifidobacterium pseudocatenulatum is not significant. For example, the standard dose (1x dose) (0.0459 mg / mL) of lactoferrin is suitable for the growth of Bifidobacterium pseudocatenulatum.

[0074] Example 5: Growth of Bifidobacterium pseudocatenulatum in MRS medium of different dosage compositions According to Example 2, the appropriate dosage of β-glucan to promote the growth of Bifidobacterium pseudocatenulatum was 4 times, then 9 times and 1 times the standard dosage. According to Example 3, the optimal dosage of N-acetylneuraminic acid was 4 times, then 10 times, 1 time and 22 times the standard dosage. According to Example 4, the optimal dosage of lactoferrin was the standard dosage (1 time). β-glucan, N-acetylneuraminic acid and lactoferrin were combined with the standard dosage ratios obtained above that can promote the growth of Bifidobacterium pseudocatenulatum (1:4:1, 9:4:1, 4:1:1, 4:10:1, 4:22:1, 4:4:1), and the combined dosages were doubled (except when the maximum amount added by law was exceeded) and doubled, respectively, The compositions of β-glucan, N-acetylneuraminic acid, and lactoferrin were prepared with standard dosage ratios of 1:4:1, 1 / 2:2:1 / 2, 2:8:2, 9:4:1, 9 / 2:2:1 / 2, 4:1:1, 2:1 / 2:1 / 2, 8:2:2, 4:10:1, 8:20:2, 2:5:1 / 2, 4:22:1, 2:11:1 / 2, 4:4:1, 2:2:1 / 2, and 8:8:2, giving a total of 16 different ratios. 1 mL of the bacterial solution of Bifidobacterium pseudocatenulatum that had been continuously activated for two generations was placed in a sterile centrifuge tube and centrifuged at 5000 r / min for 15 minutes. The upper layer medium was discarded to obtain bacterial slurry, which was then resuspended in 1 mL of sterile saline and inoculated into reduced-sugar MRS medium supplemented with the above-mentioned 16 different dosages of β-glucan, N-acetylneuraminic acid, and lactoferrin compositions at an inoculum volume of 2% (V / V). As a blank control, reduced-sugar MRS medium without any composition was inoculated, placed in a microplate reader, and cultured anaerobically at 37°C for 36 hours. During the culture, the OD of the culture solution was measured. 600 The growth curves of Bifidobacterium pseudocatenulatum at different doses of the composition are shown in Figure 5.

[0075] As can be seen from Figure 5, B. pseudocatenulatum entered the logarithmic growth phase at almost the same time in the 16 dose compositions and the control group. As can be seen from Figure 6, in the stationary phase, all of the compositions such as 4:10:1, 4:4:1, 8:8:2, 2:8:2, 9 / 2:2:1 / 2, 8:2:2, and 2:11:1 / 2 promoted the growth of B. pseudocatenulatum and increased the OD 600 In particular, the 4:10:1 composition promoted the growth of Bifidobacterium pseudocatenulatum most significantly, and the OD value was increased by 1.2 times compared to the control group. 600 The stationary phase of B. pseudocatenulatum was about 1.8 times that of the control. The 4:10:1, 4:4:1, and 8:8:2 dose compositions prolonged the stationary phase of B. pseudocatenulatum, and the nutrients available to B. pseudocatenulatum were more sufficient in these three dose compositions. The 2:8:2, 9 / 2:2:1 / 2, 8:2:2, and 2:11:1 / 2 compositions also tended to prolong the stationary phase of B. pseudocatenulatum, whereas the other dose compositions and the control conditions showed a short stationary phase and a rapid decline in B. pseudocatenulatum. Taking into consideration the overall effect of the composition in promoting the proliferation of bifidobacteria, preferred embodiments include compositions in which the β-glucan is 2 to 8 times the standard dosage, the N-acetylneuraminic acid is 2 to 11 times the standard dosage, and the lactoferrin is 0.5 to 2 times the standard dosage, with concentrations of 0.1275 to 0.5100 mg / mL, 0.1029 to 0.5660 mg / mL, and 0.0230 to 0.0918 mg / mL, respectively.

[0076] Example 6: Growth of Bifidobacterium pseudocatenulatum in MRS medium with appropriate amounts of β-glucan, N-acetylneuraminic acid, lactoferrin and composition According to Example 2, the appropriate dosage of β-glucan to promote the growth of Bifidobacterium pseudocatenulatum was 4 times the standard dosage. According to Example 3, the optimal dosage of N-acetylneuraminic acid was 4 times the standard dosage. According to Example 4, the optimal dosage of lactoferrin was the standard dosage (1x). According to Example 5, the appropriate dosage of the composition was a combination of the standard dosages of the three components at ratios of 4:10:1, 4:4:1, 8:8:2, 2:8:2, 9 / 2:2:1 / 2, 8:2:2, and 2:11:1 / 2. 1 mL of the bacterial solution of Bifidobacterium pseudocatenulatum that had been continuously activated for two generations was placed in a sterile centrifuge tube and centrifuged at 5000 r / min for 15 minutes. The upper layer medium was discarded to obtain bacterial slurry, which was then resuspended in 1 mL of sterile saline and inoculated into reduced-sugar MRS medium supplemented with the three optimal amounts of β-glucan, N-acetylneuraminic acid, lactoferrin, and the seven appropriate amounts of compositions at an inoculum volume of 2% (V / V). As a blank control, reduced-sugar MRS medium without any of β-glucan, N-acetylneuraminic acid, lactoferrin, or compositions was inoculated. The medium was placed in a microplate reader and cultured anaerobically at 37°C for 36 hours. During the culture, the OD of the culture solution was measured. 600 The ΔOD of Bifidobacterium pseudocatenulatum was measured at 4-hour intervals under the culture conditions of appropriate amounts of β-glucan, N-acetylneuraminic acid, lactoferrin and the composition. 600 The time course of the results (excluding the blank control) is shown in Figure 7. Specific values ​​are shown in Tables 1, 2 and 3.

[0077] [Table 1] JPEG2025515244000003.jpg244156JPEG2025515244000004.jpg19152

[0078] [Table 2] JPEG2025515244000006.jpg249157JPEG2025515244000007.jpg78157

[0079] [Table 3] JPEG2025515244000009.jpg246159JPEG2025515244000010.jpg22151

[0080] As can be seen from Figure 7, β-glucan (4x the standard dose), N-acetylneuraminic acid (4x the standard dose), and lactoferrin (1x the standard dose) were all able to promote the growth of Bifidobacterium pseudocatenulatum alone (ΔOD 600nm The seven ratios of the compositions selected in the example (4:10:1, 4:4:1, 8:8:2, 2:8:2, 9 / 2:2:1 / 2, 8:2:2, and 2:11:1 / 2) were also able to promote the growth of Bifidobacterium pseudocatenulatum (ΔOD 600nm was not zero. ) and ΔOD 600nm As the culture time increased, Bifidobacterium pseudocatenulatum maintained good and smooth growth, whereas the control group rapidly declined in the later stage. This indicates that the OD of the composition and the control were significantly different. 600nm The difference between the ΔOD 600nm From the data in Tables 1, 2 and 3, the increase in ΔOD under the culture conditions of the seven ratio compositions was more remarkable. 600nm In most cases, the ΔOD values ​​for β-glucan (at 4-fold standard dose), N-acetylglucan (at 4-fold standard dose), and lactoferrin (at 1-fold standard dose) alone at the same time were compared. 600nm The ΔOD values ​​were significantly higher than those of the 4:4:1, 8:8:2, 4:10:1, 8:2:2 and 2:11:1 / 2 ratios, respectively (P<0.05, P<0.01 or P<0.001). 600nmThe ΔOD values ​​were higher and this significant difference lasted for a longer period (from 8 to 36 hours). Among these compositions, also under the 4:10:1 culture conditions, the ΔOD 600nm The value was the highest, and the significant difference lasted the longest from the 4th hour to the 36th hour of culture compared with the culture conditions of β-glucan (4 times the standard dose), N-acetylneuraminic acid (4 times the standard dose) and lactoferrin (1 times the standard dose). From the above data, it can be seen that the seven compositions selected in this example can promote the growth of Bifidobacterium pseudocatenulatum to different degrees, and β-glucan, N-acetylneuraminic acid and lactoferrin have a synergistic effect on the growth of Bifidobacterium pseudocatenulatum. The conditions for bacterial growth and reproduction include sufficient nutrients, appropriate pH value, appropriate temperature, necessary gas environment, etc. Bacteria have a large surface area, vigorous metabolism, various types of metabolism, rapid growth and reproduction, and very complex growth patterns. In the example of promoting the growth of probiotics, a composition has a synergistic effect if the promoting effect of the composition is greater than the promoting effect of any substance in the composition alone, i.e., the OD of the composition medium inoculated with the strain is 600 Values ​​are the OD of the medium containing any substance alone. 600 For example, Chinese patent application No. CN202110770059.9 discloses that the composition combining longan, octopus and jujube has a higher effect of promoting the growth of multiple probiotic strains than polysaccharides alone, and the composition has a synergistic effect on probiotics.

[0081] From the above, it was further proven that the most preferable composition ratio is 2 to 8 times the standard dosage of β-glucan, 2 to 11 times the standard dosage of N-acetylneuraminic acid, and 0.5 to 2 times the standard dosage of lactoferrin, and that compositions with concentrations of 0.1275 to 0.5100 mg / mL, 0.1029 to 0.5660 mg / mL, and 0.0230 to 0.0918 mg / mL, respectively, can effectively promote the growth of Bifidobacterium pseudocatenulatum, and that there is a synergistic effect between the three. This composition can promote the growth of Bifidobacterium pseudocatenulatum by 1.8 times more than the control group (conditions without β-glucan, N-acetylneuraminic acid and lactoferrin), provide more nutrients to Bifidobacterium pseudocatenulatum, extend the stationary phase of Bifidobacterium pseudocatenulatum, and delay the decline phase, thus increasing the potential probiotic Bifidobacterium pseudocatenulatum in the intestinal tract and improving intestinal health. [Industrial Applicability]

[0082] The composition according to the present invention is widely applicable to the food, health food and other industries.

Claims

1. A medium composition comprising basic nutritional components and supplemental components including β-glucan, N-acetylneuraminic acid, and lactoferrin, A medium composition characterized in that the mass ratio of the β-glucan, N-acetylneuraminic acid and lactoferrin is (0.10-0.60):(0.08-0.70):(0.018-0.20) in terms of dry weight.

2. The composition according to claim 1, characterized in that the β-glucan is yeast β-glucan, and the N-acetylneuraminic acid is milk-derived N-acetylneuraminic acid, bird's nest-derived N-acetylneuraminic acid, or N-acetylneuraminic acid obtained by biofermentation.

3. 3. The composition according to claim 1, wherein the basic nutritional components include one or more of a protein component, a lipid component, a sugar component, a vitamin component, a mineral component, and a pH adjusting component.

4. 4. Use of the composition according to any one of claims 1 to 3 in promoting the growth of bifidobacteria, wherein the composition is used to promote the growth of bifidobacteria under anaerobic conditions.

5. Contains β-glucan, N-acetylneuraminic acid and lactoferrin, and wherein the mass ratio of the β-glucan, N-acetylneuraminic acid and lactoferrin is (0.10-0.60):(0.08-0.70):(0.018-0.20) in terms of dry weight.

6. The bifidobacterium is selected from the group consisting of Bifidobacterium pseudocatenulatum, Bifidobacterium adolescentis, Bifidobacterium infantis, Bifidobacterium bifidum, Bifidobacterium longum, and Bifidobacterium breve.

6. The composition having the proliferation-promoting effect on intestinal bifidobacteria according to claim 5, characterized in that it contains one or more of the following:

7. 7. A composition having an effect of promoting the proliferation of intestinal bifidobacteria according to claim 5 or 6, which optionally contains other nutritional components.

8. 7. A composition having an effect of promoting the proliferation of intestinal bifidobacteria according to claim 5 or 6, characterized in that it is liquid, semi-solid or solid.

9. A food comprising a composition having an effect of promoting the proliferation of intestinal bifidobacteria according to any one of claims 5 to 8, or prepared from said composition.

10. 10. The food product according to claim 9, characterized in that the food product is a powdered drink, a bakery food, a beverage, a candy, milk and dairy products, a fermented product, a flour product or an oral preparation.

Images